Benefits of growth hormone treatment on bone metabolism, bone density and bone strength in growth hormone deficiency and osteoporosis

被引:20
作者
Wuster, C [1 ]
Harle, U [1 ]
Rehn, U [1 ]
Muller, C [1 ]
Knauf, K [1 ]
Koppler, D [1 ]
Schwabe, C [1 ]
Ziegler, R [1 ]
机构
[1] Univ Heidelberg, Dept Internal Med Endocrinol & Metab 1, Med Clin, D-69115 Heidelberg, Germany
关键词
D O I
10.1016/S1096-6374(98)80016-6
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Bone mass is reduced in patients with GH deficiency (GHD) leading to an increased vertebral fracture rate and clinically significant osteoporosis. Patients with GHD of juvenile onset have reduced skeletal mineralization. When substituting GH in patients with GHD, bone turnover is increased and bone mineral density initially decreases during the first year due to the increase in remodelling space. From the experience in patients with acromegaly, cortical bone mass is increased and trabecular bone mass is normal in eugonadal or decreased in the hypogonadal patients. However, bone mineral content and bone area are increased leading to a higher biomechanical competence of bone as shown in rats. In patients with GHD of juvenile onset, mineralization and bone maturation are achieved during treatment with GH in adult life after having reached final body height leading to an increase in bone mass. The GH/IGF-I system is dysregulated in patients with post-menopausal osteoporosis. This is shown by reduced systemic IGF and IGFBP-3-levels in osteoporosis suggesting a decrease of endogenous GH-secretion or a dysregulation of the GH receptor system which is beyond the normal ageing process of the GH/IGF system, the "somatopause". A premature somatopause may be responsible for the dysregulation in some patients with osteoporosis. However, 24-h GH profiles do not differ between patients suffering from osteoporosis or osteoarthritis. Treatment of osteoporosis with GH might be beneficial due to the increased bone metabolism and improved bone geometry which occurs with GH. The substantial increase of bone remodelling achieved with GH may be helpful during late post-menopause with decreased bone turnover and impaired osteoblastic function. Using GH to prevent physiological bone loss that occurs with age seems possible, but has to be discussed on an ethical and economic basis. (C) 1998 Churchill Livingstone.
引用
收藏
页码:87 / 94
页数:8
相关论文
共 70 条
[61]   GROWTH-HORMONE TREATMENT OF ADULTS WITH GROWTH-HORMONE DEFICIENCY - RESULTS OF A 13-MONTH PLACEBO CONTROLLED CROSS-OVER STUDY [J].
WHITEHEAD, HM ;
BOREHAM, C ;
MCLLRATH, EM ;
SHERIDAN, B ;
KENNEDY, L ;
ATKINSON, AB ;
HADDEN, DR .
CLINICAL ENDOCRINOLOGY, 1992, 36 (01) :45-52
[62]   INCREASED PREVALENCE OF OSTEOPOROSIS AND ARTERIOSCLEROSIS IN PATIENTS WITH CONVENTIONALLY SUBSTITUTED PITUITARY INSUFFICIENCY - IS THERE A NEED FOR ADDITIONAL GROWTH-HORMONE SUBSTITUTION [J].
WUSTER, C ;
SLENCZKA, E ;
ZIEGLER, R .
KLINISCHE WOCHENSCHRIFT, 1991, 69 (16) :769-773
[63]   BONE MASS OF SPINE AND FOREARM IN OSTEOPOROSIS AND IN GERMAN NORMALS - INFLUENCES OF SEX, AGE AND ANTHROPOMETRIC PARAMETERS [J].
WUSTER, C ;
DUCKECK, G ;
UGUREL, A ;
LOJEN, M ;
MINNE, HW ;
ZIEGLER, R .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1992, 22 (05) :366-370
[64]  
WUSTER C, 1993, J INTERN MED, V234, P249
[65]  
WUSTER C, 1993, ACTA ENDOCRINOL-COP, V128, P14
[66]  
WUSTER C, 1995, ENDOCRINOL METAB, V2, P3
[67]  
WUSTER CHR, 1995, ENDOCRINOLOGY AGEING, P95
[68]  
WUSTER CHR, 1995, CALCIF TISSUE, V56, P469
[69]  
WUSTER CHR, 1996, EXP CLIN ENDOCRINOL, V104, P159
[70]  
WUSTER CHR, 1995, J BONE MINER RES S1, V10, pP206